Abstract

When treating children with Cerebral Palsy (CP), computational simulations based on musculoskeletal models have a great potential in assisting the clinical decision-making process towards the most promising treatments. In particular, predictive simulations could be used to predict and compare the functional outcome of a series of candidate interventions. In order to be able to benefit from these predictive simulations however, it is important to know how much information about the post-treatment patient’s motor control could be gathered from data available before the intervention. Within this paper, we quantified how much of the muscle activity measured after a treatment could be explained by subject-specific muscle synergies computed from EMG data collected before the intervention. We also investigated whether generic synergies could be used, in case no EMG data is available when running predictive simulations, to reproduce both pre- and post-treatment muscle activity in children with CP. Subject-specific synergies proved to be a good indicator of the patient’s post-treatment motor control, explaining on average more than 85% of the post-treatment muscle activity, compared to an average of 94% when applied to the original pre-treatment data. Generic synergies explained 84% of the pre-treatment and 83% of the post-treatment muscle activity on average, but performed relatively well for patients with low selective motor control and poorly in patients with more selectivity. Our results suggest that subject-specific muscle synergies computed from pre-treatment EMG data could be used with confidence to represent the post-treatment motor control of children with CP during walking. In addition, when performing simulations involving patients with a low selective motor control, generic synergies could be a valid alternative.

Highlights

  • Cerebral palsy (CP) is caused by a lesion in the developing brain and leads to a variety of movement disorders

  • While muscle synergies seem to undergo little changes after treatment, from a modelling perspective, the amount of post-treatment muscle activity that can be explained by a model of motor control based only on information collected before the treatment is still an open question. We investigated this for patients treated with botulinum toxin injections (BOTOX) and single-event multilevel surgeries (SEMLS)

  • We investigated if subject-specific synergies provide more accurate reconstructions of the pathological muscle activations than of the activations from typically developed (TD) children

Read more

Summary

Introduction

Cerebral palsy (CP) is caused by a lesion in the developing brain and leads to a variety of movement disorders. While the use of threedimensional gait analysis has proven to be successful in reducing the rate of unsuccessful treatments that require follow-up surgeries [9], musculoskeletal models and computational simulations can provide further help in selecting the most promising treatment. They would allow performing in-silico evaluation and comparison of the effects of different therapeutic interventions on the patient’s condition [10,11,12]. It is important to generate a model of the patient’s motor control that is representative of the specific impairment. It is important to know how representative of the post-operative condition a model built using only pre-operative data is, since this scenario would be the most helpful in clinical practice

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call